Upper gastrointestinal (UGI) tolerability of valdecoxib, A Cox-2 specific inhibitor, compared with nonspecific (NS) NSAIDs among patients with osteoarthritis (OA) and rheumatoid arthritis (RA)

被引：1

|

作者：

Goldstein, JL

Eisen, GM

Hanna, DB

Burke, T

机构：

来源：

GASTROENTEROLOGY | 2003年 / 124卷 / 04期

关键词：

D O I：

10.1016/S0016-5085(03)82590-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：A511 / A512

页数：2

相关论文

共 37 条

[31] The COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration.
Kivitz, A
Fisen, G
Zhao, WW
Recker, DP
Verburg, KM
ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S136 - S136
[32] Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
Karim, A
Tolbert, DS
Hunt, TL
Hubbard, RC
Harper, KM
Geis, GS
JOURNAL OF RHEUMATOLOGY, 1999, 26 (12) : 2539 - 2543
[33] Korean cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
Yun, HR
On, KT
Kim, TH
Jung, SS
Yoo, DH
Kim, SY
Bae, SC
ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S311 - S311
[34] Disease severity and costs among patients starting a treatment with COX-2 specific inhibitors versus NSAIDs patients in Italy: Quantitative assessment in 442 patients with arthritis
Lucioni, C
Chinellato, A
Mazzi, S
Roggeri, D
Chiroli, S
VALUE IN HEALTH, 2002, 5 (06) : 476 - 477
[35] Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: Quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis
Wolfe, F
Flowers, N
Burke, TA
Arguelles, LM
Pettitt, D
JOURNAL OF RHEUMATOLOGY, 2002, 29 (05) : 1015 - 1022
[36] ECONOMIC OUTCOMES FOR CELECOXIB IN LATIN AMERICA: A COST-EFFECTIVENESS STUDY OF COX-2 INHIBITORS AGAINST NSAIDS plus PPI FOR ADULT PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS IN BRAZIL, MEXICO, COLOMBIA, ARGENTINA AND COSTA RICA
Mould-Quevedo, J.
VALUE IN HEALTH, 2013, 16 (03) : A221 - A221
[37] Licofelone -: an inhibitor of 5-LOX, COX-1 and COX-2 has superior GI tolerability in OA patients compared with naproxen, regardless of low-dose aspirin co-medication, previous ulcer history or H-pylori status.
Bias, P
Buchner, A
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S72 - S72

← 1 2 3 4 →